Abstract 18022: Comparison of Moderate-Intensity Statin-Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Atherosclerotic Cardiovascular Disease
Abstract
Introduction: Residual cardiovascular risk remains substantial among patients with established atherosclerotic cardiovascular disease (ASCVD), highlighting the importance of optimizing lipid-lowering therapy. While both high-intensity statin monotherapy and moderate-intensity statin plus ezetimibe combination therapy are widely used in clinical practice, uncertainty persists regarding their relative effects on LDL-C reduction, cardiovascular outcomes, and treatment-related adverse events. Hypothesis: The addition of ezetimibe to moderate-intensity statin therapy provides lipid-lowering efficacy comparable to or greater than that achieved with high-intensity statin monotherapy without compromising safety in patients with atherosclerotic cardiovascular disease. Methods: A systematic literature search of PubMed, Embase, and the Cochrane Library was conducted from database inception through March 2026 to identify randomized and observational studies comparing moderate-intensity statin plus ezetimibe (MIS/EZT) with high-intensity statin monotherapy (HIS) in adults with atherosclerotic cardiovascular disease. Extracted data were compiled using Excel. Meta-analysis was performed using RevMan version 5.4.1 with random-effects models. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated for dichotomous outcomes, and mean differences (MD) with 95% CI were calculated for continuous outcomes. Outcomes of interest included achievement of LDL-C <70 mg/dL, achieved LDL-C levels at follow-up, major adverse cardiovascular events (MACE), and drug-related adverse events. Results: Sixteen studies comprising 6,155 patients were included. Compared with HIS, MIS/EZT was associated with a significantly greater likelihood of achieving LDL-C <70 mg/dL (OR 1.78, 95% CI 1.39-2.28; p<0.00001). MIS/EZT also achieved significantly lower LDL-C levels at follow-up (MD: –5.20 mg/dL; 95% CI: –8.39 to –2.02; p=0.001). No statistically significant difference was observed in MACE (OR 0.49, 95% CI 0.15-1.59; p=0.23). Similarly, rates of drug-related adverse events were comparable between groups (OR 0.90, 95% CI 0.51-1.60; p=0.72). Conclusion: In patients with ASCVD, moderate-intensity statin plus ezetimibe therapy was associated with superior LDL-C target attainment and greater LDL-C reduction compared with high-intensity statin monotherapy, while demonstrating similar rates of major adverse cardiovascular events and adverse drug reactions. Further studies with longer follow-up are needed to determine whether these lipid-lowering benefits translate into improved long-term cardiovascular outcomes.